Logo

CASI Pharmaceuticals, Inc.

CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel… read more

Healthcare

Biotechnology

29 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.81

Price

-2.59%

-$0.02

Market Cap

$12.549m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-328.6%

EBITDA Margin

-353.9%

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$26.846m

-5.9%

1y CAGR

-14.4%

3y CAGR

+0.0%

5y CAGR
Earnings

-$49.378m

-25.8%

1y CAGR

-12.4%

3y CAGR

-12.3%

5y CAGR
EPS

-$3.16

-23.4%

1y CAGR

-5.8%

3y CAGR

-7.3%

5y CAGR
Book Value

-$28.592m

$24.462m

Assets

$53.054m

Liabilities

$18.855m

Debt
Debt to Assets

77.1%

-0.5x

Debt to EBITDA
Free Cash Flow

$0.00

+100.0%

1y CAGR

+28.1%

3y CAGR

+30.3%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases